UpdatesGeneral Updates
JHS Svendgaard's board approved reallocating 29.99 Cr from its preferential issue.
JHS Svendgaard Laboratories LimitedJHS · Filed with the exchange
Funds shift from specific equipment/group infusion to broader Capital Expenditure & Business Expansion (11.75 Cr) and Strategic & Growth Initiatives (10.75 Cr), alongside General Corporate (7.50 Cr), for enhanced flexibility.
No comments yet. Be the first.